火把花根片联合厄贝沙坦治疗IgA肾病的临床观察

doi:10.3736/jcim20050509

Abstract

Objective

To observe the effects of Huobahuagen Tablets combined with irbesartan on the risk factors of IgA nephropathy.

Methods

Sixty-two patients diagnosed as IgA nephropathy were randomly divided into control group and treatment group. Thirty patients in the control group were treated with Huobahuagen Tablets (5 tablets po t.i.d.), and 32 patients in the treatment group were treated with irbesartan (150 to 300 mg po q.d.), besides the same treatment as the control group. After 3 months of treatment, the levels of blood pressure (BP), 24 h urine protein (Upr), urinary red blood cells (URBC), blood triglycerides (TG), total cholesterol (TC), albumin (Alb), alanine transaminase (ALT), white blood cells (WBC) and serum creatinine (Scr) were observed.

Results

After treatment, the levels of Upr, URBC and Scr in both groups were decreased, as compared with those before treatment (P<0.05 or P<0.01), and the levels of BP, Upr, URBC and Scr in the treatment group were lower than those in the control group (P<0.01). The levels of Alb in both groups were increased, as compared with those before treatment (P<0.05 or P<0.01), and the level of Alb in the treatment group was higher than that in the control group (P<0.05).

Conclusion

Huobahuagen Tablets, when used together with irbesartan, may improve the renal function of the patients with IgA nephropathy and slow the deterioration of the disease by reducing BP, Upr, URBC and Scr.

Key words: Huobahuagen Tablets, Irbesartan, Glomerulonephritis, IgA, Risk factors

CLC Number:

R692.31

Xiao-dong Guan, Yu-fang Wu, Wen Zhao. Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan. Journal of Chinese Integrative Medicine, 2005, 3(5): 366-369.

/ / Recommend

Add to citation manager EndNote| Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.jcimjournal.com/EN/10.3736/jcim20050509

http://www.jcimjournal.com/EN/Y2005/V3/I5/366

[1]	叶任高 . IgA肾病的治疗近况[J]. 中国中西医结合肾病杂志, 2004,5(2):74 doi: 10.3969/j.issn.1009-587X.2004.02.004
[2]	侯凡凡, 梁敏 . 肾实质性高血压的合理治疗[J]. 中国中西医结合肾病杂志, 2003,4(6):311-313 doi: 10.3969/j.issn.1008-1070.2002.12.001
[3]	戎殳, 胡伟新, 刘志红 , 等. 系膜增生性肾小球肾炎的新疗法—雷公藤多甙新治疗方案的疗效观察[J]. 肾脏病与透析肾移植杂志, 1998,7(5):409-414
[4]	王海燕, 王梅 . 慢性肾脏病及透析的临床实践指南(第1版)[M]. 北京: 人民卫生出版社, 2003,( 第1版):192
[5]	章友康 . 肾病综合征[A]. 见:叶任高. 内科学[M]. 第5版. 北京: 人民卫生出版社, 2000. 532-538
[6]	Shihab FS, Bennett WM, Tanner AM , et al. Angiotensin Ⅱ blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy[J]. Kidney Int, 1997,52(3):660-673 doi: 10.1038/ki.1997.380 pmid: 9291185
[7]	Wolf G, Ziyadeh FN . Renal tubular hypertrophy induced by angiotensin Ⅱ[J]. Semin Nephrol, 1997,17(5):448-454 doi: 10.1111/j.1525-139X.1997.tb00519.x pmid: 9316213
[8]	Ruiz-Ortega M, Egido J . Angiotensin Ⅱ modulates cell growth-related events and synjournal of matrix proteins in renal interstitial fibroblasts[J]. Kidney Int, 1997,52(6):1497-1510 doi: 10.1038/ki.1997.480
[9]	朱吉莉, 贾汝汉, 王学玉 , 等. 厄贝沙坦对肾硬化大鼠肾小管间质中MMP-9/TIMP-1表达的影响[J]. 基础医学与临床, 2002,22(6):554-558 doi: 10.3969/j.issn.1001-6325.2002.06.017
[10]	黄昌亚, 余秉治, 熊飞 . 火把花根片联合苯那普利治疗IgA肾病的临床观察[J]. 湖北中医杂志, 2003,25(7):17

Related Articles 15

[1]	Jie Wu, Shu-wei Duan, Hong-tao Yang, Yue-yi Deng, Wei Li, Ya-ni He, Zhao-hui Ni, Yong-li Zhan, Shan Lin, Zhi-yong Guo, Jun Zhu, Jing-ai Fang, Xu-sheng Liu, Li-hua Wang, Rong Wang, Nian-song Wang, Xiao-hong Cheng, Li-qun He, Ping Luo, Shi-ren Sun s, Ji-feng Sun, Ai-ping Yin, Geng-ru Jiang, Hong-yu Chen, Wen-hu Liu, Hong-li Lin, Meng Liang, Lu Ma, Ming Chen, Li-qun Song, Jian Chen, Qing Zhu, Chang-ying Xing, Yun Li, Ji-ning Gao, Rong-shan Li, Ying Li, Hao Zhang, Ying Lu, Qiao-ling Zhou, Jun-zhou Fu, Qiang He, Guang-yan Cai, Xiang-mei Chen. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. Journal of Integrative Medicine, 2021, 19(2): 111-119.
[2]	Xue-yang Song, Si-jing Wang, Zhao-xia Xu, Yi-ming Hao, Lu Feng, Xiao-dong Ding, Hui Gao, Yi-qin Wang. Preliminary study on phonetic characteristics of patients with pulmonary nodules. Journal of Integrative Medicine, 2020, 18(6): 499-504.
[3]	Morufu Eyitayo Balogun, Elizabeth Enohnyaket Besong, Jacinta Nkechi Obimma, Ogochukwu Sophia Mbamalu, Fankou Serges Athanase Djobissie. Protective roles of Vigna subterranea (Bambara nut) in rats with aspirin-induced gastric mucosal injury. Journal of Integrative Medicine, 2018, 16(5): 342-349.
[4]	Yi Chen, De-yu Fu, Yu Chen, Yan-ming He, Xiao-dong Fu, Yan-qiu Xu, Yi Liu, Xiao-tao Feng, Teng Zhang, Wen-jian Wang. Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: A randomized, placebo-controlled trial. Journal of Chinese Integrative Medicine, 2013, 11(3): 184-194.
[5]	Jie-ning Wang, Sheng Ye, Dong-hai Yu, Hui Zhao, Le-yi Du. Practice and exploration on clinical evaluations of hospital-made Chinese herbal formulas in the Pudong New Area of Shanghai. Journal of Chinese Integrative Medicine, 2012, 10(10): 1084-1087.
[6]	Liang-ping Hu, Xiao-lei Bao. General issues and precautions in the design for clinical trials of investigational new drugs. Journal of Chinese Integrative Medicine, 2011, 9(2): 138-142.
[7]	Yin Fan Arthur, LixingLao, Rui-xin Zhang, An-nan Zhou, Brian M. Breman. Preclinical safety evaluation of the aqueous acetone extract of Chinese herbal formula Modified Huo Luo Xiao Ling Dan. Journal of Chinese Integrative Medicine, 2010, 8(5): 438-447.
[8]	Feng Tian , Yan-ming Xie. Real-world study: A potential new approach to effectiveness evaluation of traditional Chinese medicine interventions. Journal of Chinese Integrative Medicine, 2010, 8(4): 301-306.
[9]	Ling Li , Fang-guo Lu, Qing-hu He. Efficacy of Maxing Shigan Decoction combined with Western medicine for pneumonia in children: A systematic review and meta-analysis. Journal of Chinese Integrative Medicine, 2009, 7(9): 809-813.
[10]	Wang Hui-chun, Zuo Chuan-tao, Guan Yi-hui. Research on receptors related to acupuncture analgesia and positron emission tomography radioligands: A review. Journal of Chinese Integrative Medicine, 2009, 7(6): 575-581.
[11]	Ying Shen , Ji-di Lu . Treatment of adjuvant arthritis in rats with Chinese herbal fumigation: Efficacy and mechanism. Journal of Chinese Integrative Medicine, 2009, 7(2): 157-162.
[12]	De-chang Hu , Xiu-tian Guo, Yong-qing Cao. Segmenting jugged dissection and ligation combined with additional ligation in treating circular mixed hemorrhoids: a report of 63 cases. Journal of Chinese Integrative Medicine, 2009, 7(12): 1181-1183.
[13]	Nan-nan Chen, Shi-lin Huang, Yang Xiang, Li Zhang, De-jie Zhang. Effects of psoralen plus long-wave ultraviolet-A on apoptosis of HL-60 leukemia cells. Journal of Chinese Integrative Medicine, 2008, 6(8): 852-855.
[14]	Jia Guo, Zong-wen Huang, Jing-yun Fan, Yan chen, Fu-qian He. Risk factor analysis of severe acute pancreatitis complicated by pancreatic encephalopathy. Journal of Chinese Integrative Medicine, 2008, 6(4): 352-354.
[15]	Yi-heng Liu, Hai-ying Zhang, Hong-min Zang, Jun-chang Cheng, Yan-min Li. Effects of Kangfengshi Granules on expressions of osteoprotegerin, RANKL and M-CSF in bone tissues of rats with collagen-induced arthritis. Journal of Chinese Integrative Medicine, 2006, 4(3): 307-310.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2]	Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3]	Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4]	SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5]	Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6]	Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7]	Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8]	Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9]	Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10]	Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239

Group	n	Systolic pressure	Diastolic pressure
Control group
Before treatment	30	150.0±22.6	96.8±12.2
After treatment	30	148.6±21.8	96.4±12.6
Treatment group
Before treatment	32	152.0±22.8	98.5±11.6
After treatment	32	128.8±13.4**^△△	84.7±7.9**^△△

Group	n	Upr (g/24 h)	URBC (cells/HP)	Scr (μmol/L)	Alb (g/L)	TG (mmol/L)	TC (mmol/L)	ALT (U/L)	WBC (109/L)
Control group
Before treatment	30	2.24±1.32	37.5±17.5	212.8±60.4	31.6±5.8	2.59±1.35	6.98±2.74	37.92±4.56	6.32±1.62
After treatment	30	0.98±0.42**	16.5±9.5**	182.4±36.2*	35.2±6.8*	2.52±1.27	6.86±2.65	39.86±9.26	5.52±1.48
Treatment group
Before treatment	32	2.26±1.27	38.5±16.5	216.4±56.2	31.4±5.6	2.65±1.32	6.63±2.65	37.10±4.62	6.20±1.60
After treatment	32	0.46±0.22**^△△	9.5±6.5**^△△	128.6±36.4**^△△	38.8±7.3**^△	2.58±1.24	6.23±2.83	40.13±9.31	5.46±1.52

Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan

RichHTML

PDF (PC)

Like

Abstract

Cite this article

Share this article

TrendMD

Figures/Tables 2

References 10

Related Articles 15

Metrics

Comments

Recommended 10